Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Default Payment Of ASP+6% For Hospital Outpatient Drugs Has Industry Support

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS says default for reimbursement of Medicare Part B drugs used in hospital outpatient settings will be average sales price plus 6% as it seeks to improve methods of calculating a proper reimbursement rate based on data provided by hospitals. The rate has fluctuated year-to-year, from ASP+4% to ASP+6%, under the previous formula.

You may also be interested in...



Medicare Payments For Hospital Outpatient Drugs Set At ASP+6% For 2013

CMS issues its final 2013 hospital outpatient prospective payment system rule for Medicare Part B. The ASP+6% payment rate for drugs is aimed at producing more predictable reimbursement for separately billable drugs, biologics and radiopharmaceuticals.

CMS Methodology, Not Industry Complaints, Brings Proposed Hospital Part B Outpatient Drug Reimbursement Back To ASP+6% in 2011

Agency calls rate a "coincidental outcome" in its proposed update to the Medicare hospital outpatient prospective payment system for 2011.

FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees

Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS074633

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel